Sophia Graeff Buhl Nielsen
JPMorgan Chase & Co, Research Division
Good afternoon, and welcome to the Zealand session of the 44th JPMorgan Healthcare Conference. My name is Sophia Graeff Buhl-Nielsen. I’m an analyst here at JPMorgan on the European pharma and biotech team. And today, it’s my pleasure to welcome Adam Steensberg, the CEO of Zealand Pharma to the conference. [Operator Instructions]
With that, over to you, Adam.
Adam Steensberg
President & CEO
Thank you, and great to be here, and welcome, everyone. So what better way to kick start what looks to be the most exciting year in Zealand’s more than 25 years history in working in metabolic health. A few weeks ago, we launched our Metabolic Frontier 2030 strategy and ambition to really go in and do our part to address what we consider as the biggest health care challenge of our time, and that’s the obesity pandemic and all the diseases that follows the obesity pandemic.
What I will discuss today is, of course, our focus coming into the year. But also, I just want to remind all of us that we have actually only taken the first baby steps to address this health care pandemic with what we have seen playing out in the markets these days. We need significant new innovations if we are to get around it.
Zealand Pharma, if you think about where we’re going to take the company in the coming years, it’s about becoming a generational biotech leading in metabolic health, changing the landscape and chasing the opportunities for the many patients who live
